p16mRNA在乳腺癌中的表达及临床病理意义

In situ hybrid detection of p16 mRNA in primary breast carcinoma: its clinicopathologic significance

目的探讨ｐ１６ｍＲＮＡ在原发性乳腺癌的表达情况及其临床病理意义。方法体外转录法生物素标记ＲＮＡ探针，用原位杂交技术检测ｐ１６ｍＲＮＡ在１２０例乳腺癌标本中的表达。结果ｐ１６ｍＲＮＡ的阳性表达率７０８％（８５／１２０），与患者年龄、肿瘤大小及雌、孕激素受体状态无相关性；淋巴结转移组的阳性率５４％（３１／５７），未转移组８６％（５４／６３）（Ｐ＜００１）；ｐ１６ｍＲＮＡ表达阳性组的３年以上病死率为２５％（２１／８５），阴性组为５７％（２０／３５）（Ｐ＜００１）。结论ｐ１６ｍＲＮＡ的异常表达在乳腺癌的发生发展中可能起重要作用。

Objective To investigate the expression of p16 mRNA in primary breast carcinoma and its clinicopathological significance. Methods In vitro transcriptional RNA probe labeled with biotin and in situ hybridization method were used in this study to detect p16 mRNA in the paraffin embedded tissue of human primary breast carcinoma from 120 cases. Results 85 breast carcinomas showed expression of p16 mRNA with a positive rate of 70 8%. The p16 mRNA expression was not obviously correlated with patient age, tumor size, estrogen and progesterone receptor status ( P >0.05), but the positive rate of 54.4% for the lymph node metastasis group was significantly lower than 85.7% of the non metastasis group ( P <0.001). Moreover, the positive rate of 58.3% for the poor differentiate invasive duct carcinoma was also lower than that 89.7% for the well differentiated ( P <0.05). The patients after operation were followed up. The mortality of 25% (21/85) in the p16 mRNA positive group was significantly lower than that of the negative group 57% (20/35) ( P <0.01). Conclusion Abnormal expression of p16 mRNA may play animportant role in the development of human breast carcinoma.